Navigation Links
Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/IDSA Joint Meeting
Date:10/26/2008

- Once-a-Day Radezolid Clinically and Microbiologically As Effective As Twice-a-Day Linezolid When Used to Treat a Variety of uSSSIs -

NEW HAVEN, Conn., Oct. 26 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc. ("Rib-X" or the "Company"), a development-stage company focused on the discovery, development and commercialization of novel antibiotics for the treatment of antibiotic-resistant infections, today announced positive results from a Phase 2 clinical trial with the oral form of its compound, radezolid (RX-1741), for the treatment of uncomplicated skin and skin structure infections (uSSSI). These results were announced at the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)/Infectious Diseases Society of America (IDSA) 46th annual meeting (2008 ICAAC/IDSA Joint Meeting) held October 25 - 28 in Washington, D.C.

The open-label trial met both its primary (efficacy) and secondary (safety) endpoints. All doses of radezolid were as efficacious as linezolid (Zyvox(R), currently marketed by Pfizer) and demonstrated a good safety profile. The study also showed that radezolid was approximately four times more potent than linezolid against bacteria cultured from subjects in the study, including against methicillin-resistant Staphylococcus aureus (MRSA), with MIC90s of 0.5mg/L and 2.0mg/L respectively. MIC90s for other relevant bacterial isolates in the study were 0.5mg/L and 2.0mg/L for MRSA and 0.25mg/L and 1.0ug/ml for Streptococcus pyogenes for radezolid and linezolid, respectively. MIC90 is defined as the minimum inhibitory concentration necessary to inhibit the growth of 90 percent of the bacteria.

"We are pleased to report that our novel oxazolidinone, radezolid, may provide a safe and more potent alternative to the only currently marketed drug in this antibiotic class," said Susan Froshauer, PhD, President and CEO of Rib-X Pharmaceuticals. "In particular, radezolid offers a broader spectrum that includes atypicals an
'/>"/>

SOURCE Rib-X Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Rib-X Pharmaceuticals to Present at 10th Annual Superbugs & Superdrugs Conference
2. Rib-X Pharmaceuticals Renews Collaborative Agreement with the Medical Research Council
3. Rib-X Pharmaceuticals Initiates Phase 2 Trial for RX-3341 In Complicated Skin and Skin Structure Infections
4. Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... , May 21, 2013   Regulus Therapeutics Inc ... the discovery and development of innovative medicines targeting microRNAs, ... , Ph.D., Chief Operating Officer and Executive Vice President, ... Bank 38th Annual Healthcare Conference on Wednesday, May 29, ... held at the Westin Boston Waterfront Hotel. ...
(Date:5/21/2013)... JOSE, Calif. , May 21, 2013 ... the prestigious 2013 TiE50 "Top Startup" Award at TiEcon ... its innovation, strong management team and quality of entrepreneurial ... at the Santa Clara ... a highly influential list of the most enterprising startup ...
(Date:5/21/2013)... N.J. , May 21, 2013 ... company, today announced that 13-year veteran ... Executive Officer. Geraghty,s experience includes more than 20 ... management positions with manufacturing organizations. He succeeds ... after serving as Kepner-Tregoe,s Chairman of the Board ...
Breaking Medicine Technology:Regulus to Present at Deutsche Bank 38th Annual Healthcare Conference 2RenovoRx Named Winner of 2013 TiE50 "Top Startup" 2Kepner-Tregoe, Inc. Promotes Chris Geraghty to Chief Executive Officer 2Kepner-Tregoe, Inc. Promotes Chris Geraghty to Chief Executive Officer 3
... May 5, 2011 Today, the Consumer Healthcare ... (OTC) single-ingredient liquid pediatric acetaminophen medicines, announces plans ... concentration. While the transition is taking place, starting ... use their current products with confidence as current ...
... As interventional cardiologists increasingly perform angiography or ... versus femoral (groin or upper leg) access, it ... guidelines, according to the first report from the ... Working Group released today at the SCAI 2011 ...
Cached Medicine Technology:OTC Industry Announces Voluntary Transition to One Concentration of Single-Ingredient Pediatric Liquid Acetaminophen Medicines 2SCAI Releases First Report on Transradial Access for Angioplasty and Stenting 2SCAI Releases First Report on Transradial Access for Angioplasty and Stenting 3
(Date:5/21/2013)... (PRWEB) May 21, 2013 DISCcert has ... showing how to use 17 DISC applications at the ... a natural progression. , The July 25 & 26th ... top 17 ways of applying DISC. The time-tested, proven ... graduates. The user-friendly DISC training materials ; ...
(Date:5/21/2013)... New York, New York (PRWEB) May 21, 2013 ... dedicated to protecting the rights of victims injured by ... the Journal of Bone & Joint Surgery on May ... (MRI) can be used to identify complications that occur ... have any symptoms of failure. ( http://www.jbjs.org/article.aspx?articleid=1684770 ) ...
(Date:5/21/2013)... stent, which is a novel stent platform eluting ... the Xience Prime everolimus-eluting stent for the primary ... nine months in the results of an imaging ... BIOFLOW-II substudy used intravascular ultrasound (IVUS) and optical ... and stent apposition at nine months after treating ...
(Date:5/21/2013)... 21, 2013 Phoseon Technology will present ... the 20th Annual IMI European Ink Jet Conference ... leader, Phoseon continues to invest in product development to ... of UV LED curing in printing applications. Phoseon ... the market offering both air cooled and water cooled ...
(Date:5/21/2013)... AURORA, Colo. (May 21, 2013) A paper recently ... and co-written by physicians and scientists at the ... important genetic risk factor for pulmonary fibrosis can be ... lung disease. , Researchers looked at a fairly common ... is a component of the mucous produced by the ...
Breaking Medicine News(10 mins):Health News:DISCcert Offers 17 Applications in Coming DISC Certification 2Health News:DISCcert Offers 17 Applications in Coming DISC Certification 3Health News:DISCcert Offers 17 Applications in Coming DISC Certification 4Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 2Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 3Health News:Biodegradable stent proves non-inferior to drug-eluting stent 2Health News:Researchers find genetic risk factor for pulmonary fibrosis 2
... Brook Hills Marriott Resort Sponsors Scottish-Themed Charity Event , , OAK BROOK, ... marks an important night at the Oak Brook Hills Marriott Resort in Illinois. ... Hills resort will be hosting the Oak Brook Hills Golf Classic ... Hills Golf Classic will feature: , , , ...
... Technology into New Pulmonary Markets - , , AUSTIN, ... delivery company, today announced that it has closed its Series ... of Savara,s existing investors participated in the round, which was ... Savara will utilize the funds to continue development of its ...
... University professor is among the first in the country ... economic stimulus efforts. Robert Miranda Jr., assistant professor ... Addition Studies, will use the funds in an unusual ... by testing a novel medication. "There are very ...
... America,s Web Site for Concerned Consumers; GlaxoSmithKline, Merck Rated Highest, ... , , WASHINGTON, June 9 ... or bad companies? That is the question that is ... consumer watchdog Web site, ResponsibleShopper.org ( http://www.ResponsibleShopper.org ...
... PEMBROKE, Bermuda, June 9 Allied ... today announced that John Gauthier, Senior,Vice President and Chief ... Bureau of Economic Research (NBER) Insurance Project Workshop in,Cambridge, ... discuss,asset allocation and other financial policies of insurers and ...
... good vision as part of their occupation. However, radiologists ... testing. A new study found that approximately 50% of ... vision tested or it had been 24 months or ... study, performed at the University of Maryland School of ...
Cached Medicine News:Health News:Oak Brook Hills Golf Classic to Benefit the Children's Miracle Network 2Health News:Savara Closes Series A Financing Round 2Health News:Early stimulus funding supports research in adolescent addiction 2Health News:ResponsibleShopper.org: What Do You Know About The Companies In Your Medicine Cabinet? 2Health News:ResponsibleShopper.org: What Do You Know About The Companies In Your Medicine Cabinet? 3Health News:ResponsibleShopper.org: What Do You Know About The Companies In Your Medicine Cabinet? 4Health News:Allied World's John Gauthier to Participate in a Panel at the NBER Insurance Project Workshop, June 10, 2009 2
... combination of the Aliquoting System RSD 800A ... ACM-8). This turns out in an efficient ... laboratory. The System automates all important front-end ... via cap identification, sample quality control, decapping, ...
... Aliquoting System RSD 800A is an individually ... archiving (additional tube type identification via cap ... process various sample tubes in a clearly ... areas are customized and offer high capacity. ...
... System RS 800 can sort different specimen ... sorting are not necessary anymore and all ... a very timesaving and economical way ... a Tube Type Identification via Cap Recognition ...
... provide molecular labs a more advanced alternative ... our MGB technology, combined with post-PCR dissociation ... to provide molecular labs more powerful tools ... organisms or genetic mutations associated with disease, ...
Medicine Products: